ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1837

Enhanced Mitochondrial Activity in B cells from Females Is Required to Drive Increased T-bet Induction by TLR7 in Lupus
Abstract Number: 1838

Differential Expression Of Activation Markers On dsDNA-reactive B-cells Between Healthy Subjects And SLE Patients Reveals Unconventional Extrafollicular Activation In SLE
Abstract Number: 1839

Transcriptional Profiling of Whole Blood and Kidney Biopsy Samples from Lupus Nephritis and IgA Nephropathy Patients Suggests Different Disease Pathways
Abstract Number: 1840

Breathomics in Systemic Lupus Erythematosus: uncovering non-invasive markers of disease activity
Abstract Number: 1841

Differential metabolomic signatures along lupus nephritis spectrum
Abstract Number: 1842

Social Vulnerability Index, Type 2 Lupus Symptoms, and Select Dysregulated Immune Features Identify Stage 2 (Pre-classification) SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Abstract Number: 1843

Tissue Neutrophils in The Pathogenesis of Lupus Nephritis
Abstract Number: 1844

Disease-Associated Macrophages Express an Injury-Associated Gene Program and Localize to Distinct Compartments in Proliferative and Mixed Histologic Classes of Lupus Nephritis
Abstract Number: 1845

Immune Cell Profiles and Transcriptomic Signatures of Atherosclerosis in Systemic Lupus Erythemathosus
Abstract Number: 1846

Integrated spatial and single-cell profiling of treatment-naïve lupus nephritis biopsies
Abstract Number: 1847

Spatial transcriptomics reveals a complex microanatomic patterning of complement mediated inflammation and fibrosis in Class III pediatric lupus nephritis associated with local histologic injury
Abstract Number: 1848

DS-7011a, An Anti-TLR7 Antagonistic Monoclonal Antibody, Suppresses Human Immune Cells and Multiple Cytokines/Chemokines Related to the Pathogenesis of SLE
Abstract Number: 1849

Time-course RNA sequencing analysis of longitudinal peripheral blood samples to elucidate the factors determining treatment resistance in systemic lupus erythematosus
Abstract Number: 1850

First American SLE patients demonstrate enhanced lipid metabolism and B cell activation by high-content proteomic analyses
Abstract Number: 1851

Endotype Discovery in Systemic Lupus Erythematosus Using Multi-Omic Approaches: Toward Precision Insights into Cardiovascular and Renal Damage

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].